SGI
SGMO

Summit Global Investments’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Summit Global Investments’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-29,636
Closed -$371K – 620
2021
Q1 		$371K Buy
+29,636
New +$399K 0.02% 415

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Summit Global Investments's SGMO Position: Q2 2021 in Review

Summit Global Investments sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2021, closing a stake of 29,636 shares — an estimated $371K sold.

Summit Global Investments first reported a position in SGMO in Q1 2021 and held it in 1 quarter. The position peaked at $371K in Q1 2021. 197 funds tracked by Wall St. Rank hold SGMO as of Q2 2021.

  • Summit Global Investments reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2021 after selling out during the quarter.
  • Summit Global Investments sold 29,636 SANGAMO THERAPEUTICS INC shares in Q2 2021, an estimated $371K.
  • Summit Global Investments first reported a position in SANGAMO THERAPEUTICS INC in Q1 2021 and held it in 1 quarter.
  • Summit Global Investments's SANGAMO THERAPEUTICS INC position peaked at $371K in Q1 2021.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2021.

Based on Summit Global Investments's 13F filing for Q2 2021, filed 28 Jan 2022.